根据最新提交至美国证券交易委员会（SEC）的文件，一项诉讼指控生物技术公司Ocular Therapeutix针对EyePoint公司及其产品Duravyu散布了不实信息。该法律文件指出，Ocular Therapeutix通过公开声明传播了有关EyePoint业务及Duravyu产品的虚假内容。目前案件细节仍在进一步披露中，此事可能对两家公司的市场声誉及投资者关系产生重要影响。
根据最新提交至美国证券交易委员会（SEC）的文件，一项诉讼指控生物技术公司Ocular Therapeutix针对EyePoint公司及其产品Duravyu散布了不实信息。该法律文件指出，Ocular Therapeutix通过公开声明传播了有关EyePoint业务及Duravyu产品的虚假内容。目前案件细节仍在进一步披露中，此事可能对两家公司的市场声誉及投资者关系产生重要影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.